CPT 81479 is the Current Procedural Terminology code labeled “Unlisted molecular pathology procedure,” and it functions as a catch-all billing code for molecular and genetic tests that do not yet have their own specific CPT code. When a laboratory performs a test that is too new, too specialized, or too proprietary to match any of the hundreds of existing molecular pathology codes, 81479 is the code that gets submitted to insurers. The result is a code that can represent wildly different tests at wildly different price points, which creates persistent friction between laboratories, insurers, and patients.
Why a Catch-All Code Is Necessary
The CPT code set, maintained by the American Medical Association, assigns specific numeric codes to medical procedures so that everyone in the billing chain speaks the same language. In molecular pathology, there are codes for specific gene analyses, multi-gene panels, and various sequencing techniques. But the pace of innovation in genetic and genomic testing consistently outstrips the code-creation process. A laboratory might develop a new multi-gene panel for a rare disease, validate it clinically, and begin offering it to patients well before the AMA has created a code that accurately describes it. In the interim, the lab needs some way to bill for the work.
That is where 81479 comes in. It exists in virtually every CPT subsection as a pressure valve. Just as there are “unlisted” codes in surgery, radiology, and other specialties, 81479 serves molecular pathology. The code does not describe what was done; it simply signals that a molecular pathology procedure was performed and that it does not fit neatly into the existing code menu. The laboratory is then expected to submit supporting documentation explaining exactly what the test is, why it was ordered, and what it costs.
The Rapid Growth of 81479 Spending
The scale of testing billed under 81479 has grown enormously. Medicare payments under this undefined code climbed from roughly $4 million in 2013 to $288 million in 2020, a surge that reflects how fast new molecular tests have entered clinical practice without receiving their own CPT codes.1Journal of Law and the Biosciences. Payer reimbursement practices and incentives for improving interpretation of germline genetic testing That seventy-fold increase happened over just seven years, and it was driven in part by the explosion of next-generation sequencing. Labs rapidly adopted large multi-gene panels that did not map cleanly onto older, single-gene CPT codes, so they reported them under the unlisted bucket.
To put that spending in context, the same data showed that expenditures for the BRCA1/2 sequencing code 81162, one of the most well-known and commonly billed molecular tests in cancer genetics, peaked at about $118 million in 2019. That means by 2020, the generic unlisted code was absorbing more than twice the spending of one of the most established genetic tests in oncology. The imbalance illustrates how much molecular testing activity exists in a coding gray zone.
Why Payers Struggle with 81479
From an insurer’s perspective, 81479 is an opaque box. A specific CPT code tells a payer what test was done, which means the payer can check it against coverage policies, compare its price to benchmarks, and make a medical necessity determination relatively quickly. With 81479, none of that is automatic. The code could represent a $200 single-gene assay or a $5,000 comprehensive genomic profiling panel. Without additional information, payers find it difficult to determine whether a test billed under a generic code is medically necessary.2The Journal of Applied Laboratory Medicine. Payment Matters: Understanding Payer Perspectives on Laboratory Stewardship
This ambiguity creates a structural problem. The payer cannot simply look up a fee schedule for 81479 the way it can for a named test. Instead, it has to review whatever documentation the laboratory attached, compare the test to something it already covers, and decide on a price. That process is slower, more labor-intensive, and more likely to result in a denial or a reimbursement amount the lab did not expect.
How Medicare Sets Prices for Unlisted Tests
When Medicare encounters a new clinical diagnostic laboratory test, including one billed under 81479, it generally uses one of two methods to set a payment rate. The first is crosswalking, where the agency decides the new test is comparable to an existing test and pays the same rate. The second is gap-filling, used when no reasonable comparison exists, in which Medicare Administrative Contractors set rates based on resources, charges, and other cost data, with those rates later adjusted based on private-payer rates collected under the Protecting Access to Medicare Act.1Journal of Law and the Biosciences. Payer reimbursement practices and incentives for improving interpretation of germline genetic testing
Both methods have limitations when applied to unlisted codes. Crosswalking works well when the new test genuinely resembles something already on the books, but many tests billed under 81479 are novel enough that no clean comparison exists. Gap-filling is more flexible but also more subjective, and it can produce payment amounts that vary by region and by contractor. For laboratories, the result is unpredictable reimbursement. For patients, it means their out-of-pocket costs can be hard to estimate in advance.
Common Reasons for Claim Denials
Claims submitted under 81479 face higher denial rates than claims with specific CPT codes, and the reasons tend to cluster around a few recurring themes. One of the most common is an “experimental or investigational” determination. Because many tests billed under 81479 are newer or use proprietary methodologies, payers frequently classify them as unproven, even when the laboratory considers them clinically validated. This is especially common when the payer has not yet developed a coverage policy that addresses the specific test.
Another frequent denial reason is insufficient documentation of medical necessity. Payers want to see a clear clinical rationale for why this particular molecular test was needed for this particular patient, and why an existing covered test could not answer the clinical question. When the supporting documentation does not make that case convincingly, the claim gets rejected. Related to this, some payers deny claims because the laboratory did not provide an adequate comparison to a similar covered procedure, which the payer needs for pricing.
Prior authorization failures also contribute. Many payers require pre-approval for any test billed under an unlisted code, and obtaining that approval retroactively through an appeal is substantially harder than getting it prospectively. Laboratories that skip the prior authorization step, whether by oversight or because turnaround time is critical, frequently run into denials that are difficult to overturn.
What This Means for Patients
The billing complications around 81479 often land squarely on patients. When a claim is denied, the patient may receive a bill for the full price of the test, which for complex genomic panels can run into the thousands of dollars. Even when the claim is not denied outright, the reimbursement amount may be lower than what the laboratory charged, leaving the patient responsible for the difference if the lab is out of network or if the plan applies a balance after partial payment.
Patients are also affected in a less visible way. Research that relies on insurance claims data to track how often genetic tests are used can miss tests billed under 81479 entirely, because the code does not specify what was performed. One study examining pharmacogenetic testing in a managed care population noted that patients who received genetic tests coded under 81479 were essentially invisible in the data, lumped together with every other unlisted molecular procedure rather than counted as recipients of a specific test.3Genetics in Medicine. The landscape of pharmacogenetic testing in a US managed care population This makes it harder to study utilization patterns, identify disparities in access, and build the evidence base that payers want to see before they agree to cover a test.
Strategies for Reducing Denial Risk
For laboratories and ordering clinicians, reducing the chance of an 81479 denial comes down to documentation and communication. The most effective step is providing a detailed description of the test with every claim. This means specifying the genes or analytes being tested, the methodology used, the clinical indication, and the peer-reviewed evidence supporting the test’s clinical utility. A bare claim with just the 81479 code and a diagnosis code is almost asking for a denial.
Prior authorization, while time-consuming, is another layer of protection. When a payer has agreed in advance that a test is medically necessary, the claim is far less likely to be rejected later. Some laboratories have dedicated teams that handle prior authorization for unlisted codes, and ordering physicians can help by providing letters of medical necessity that explain the patient’s clinical situation and why no existing covered test would suffice.
If a denial does happen, appeals should include a comparison to the most similar covered test, evidence from clinical guidelines or published literature supporting the test, and a clear explanation of how the test result will change patient management. Payers are more receptive to appeals that frame the test in terms they already use for coverage decisions: clinical validity, clinical utility, and impact on outcomes.
How Tests Move from 81479 to Their Own Codes
A test does not stay under 81479 permanently if it becomes widely adopted. The AMA’s CPT Editorial Panel reviews proposals for new codes on a regular cycle. A laboratory, professional society, or other stakeholder can submit an application describing the test, its clinical use, and the volume of testing being performed. If the panel agrees that the test is distinct enough and used frequently enough to warrant its own code, a new code is created and published in the next CPT code set update.
This migration process explains some of the spending patterns in molecular pathology. When multi-gene cancer panels first emerged, many were billed under 81479 because no panel-specific codes existed. As the AMA created codes for hereditary breast cancer panels, Lynch syndrome panels, and other defined groupings, some of that testing volume shifted from 81479 to the new specific codes. But the overall 81479 spending continued to climb, because new tests kept entering the market faster than codes could be created for them.1Journal of Law and the Biosciences. Payer reimbursement practices and incentives for improving interpretation of germline genetic testing
The BRCA testing story is a good example of how convoluted this gets. Laboratories had largely shifted to next-generation sequencing-based multi-gene panels by around 2012, but the CPT code for BRCA1/2 non-panel sequencing (81162) continued to see growing expenditures through 2019, reaching over ten times the spending on the breast cancer panel code 81432.1Journal of Law and the Biosciences. Payer reimbursement practices and incentives for improving interpretation of germline genetic testing This mismatch between what labs were actually doing in the laboratory and the codes they were billing under highlights a broader truth about CPT coding in molecular pathology: the codes often lag behind the clinical reality by years.
The Z-Code and ADLT Alternatives
Some laboratories try to work around the 81479 problem by obtaining proprietary test-specific identifiers. The AMA offers a Z-code system (sometimes called PLA codes, for Proprietary Laboratory Analyses) that allows a manufacturer or laboratory to obtain a unique code for a specific test performed by a specific lab. These PLA codes have the advantage of being specific and trackable, but they are tied to one laboratory’s version of a test and do not generalize across the industry the way standard CPT codes do.
Medicare also has the Advanced Diagnostic Laboratory Test (ADLT) designation, which applies to tests that meet certain criteria around FDA clearance or approval and single-source availability. ADLTs receive their own payment rates and are not subject to the same crosswalking or gap-filling uncertainty that affects generic unlisted codes. However, obtaining ADLT status is a lengthy process, and it applies only to a narrow set of tests.
For the many tests that do not qualify for a PLA code or ADLT status and have not yet received a specific CPT code, 81479 remains the default. This means the code is not going away anytime soon. As long as molecular diagnostics continues to innovate rapidly, there will be a gap between what labs can do and what the coding system can describe, and 81479 will continue to fill that gap.
The Perverse Incentives Around Unlisted Codes
The 81479 situation creates some uncomfortable incentive misalignments. For laboratories, billing under an unlisted code means accepting reimbursement uncertainty but also having some freedom to set their own charges, since there is no established fee schedule line item. Some labs have been accused of using 81479 to bill at higher rates than they would receive under a specific code that might carry a lower reimbursement ceiling. Whether or not that is widespread, the perception alone makes payers more skeptical of 81479 claims.
For payers, the incentive runs in the opposite direction. Denying 81479 claims is easier to justify than denying claims for recognized tests, because the payer can point to the lack of a specific code as evidence that the test is unproven or experimental. This creates a circular problem: a test cannot get enough utilization data to support a coverage determination if claims keep getting denied, and claims keep getting denied partly because there is not enough utilization data.
Patients are caught in the middle, often unaware that the billing code assigned to their test has any bearing on whether their insurance will cover it. A patient whose oncologist orders a comprehensive genomic profiling panel has no reason to know or care that the test is billed under an unlisted code. But when the explanation of benefits arrives with a denial, the code suddenly matters a great deal.
Pharmacogenomic Testing and the Visibility Problem
One area where 81479 has had a particularly muddying effect is pharmacogenomics, the use of genetic information to guide drug prescribing. Many pharmacogenomic tests examine how a patient metabolizes specific medications, and this information can influence drug choice and dosing. But because pharmacogenomic testing has evolved rapidly and encompasses a wide variety of gene-drug combinations, a significant portion of these tests end up billed under 81479 rather than under one of the more specific pharmacogenomic CPT codes.
The downstream consequence is that insurance claims databases undercount pharmacogenomic testing. Researchers trying to measure how often these tests are used, who is getting them, and whether they improve outcomes have a blind spot wherever 81479 appears, because the code does not reveal what type of molecular test was performed.3Genetics in Medicine. The landscape of pharmacogenetic testing in a US managed care population This makes it harder to build the population-level evidence that could eventually convince more payers to cover these tests routinely, perpetuating the cycle of limited coverage and limited data.
The irony is that pharmacogenomic testing is one of the areas where the clinical rationale for molecular testing is fairly intuitive: test before prescribing to avoid adverse drug reactions or therapeutic failures. Yet the billing infrastructure has not kept pace, and the result is that a meaningful chunk of pharmacogenomic testing is administratively invisible, lumped under a code that tells payers and researchers almost nothing about what was actually done.